Individualized treatment benefits advanced cancer patients

04/20/2009 | Forbes

An Arizona research team found molecular targets in 98% of 66 patients studied, and 18 people had longer progression-free survival times with targeted therapy compared to previous generalized therapies they had tried. A separate Italian study found genetic mutations in patients with advanced colorectal cancer that could indicate their tumors wouldn't respond to specific drugs.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA